Skip to Content
  • Previous Rank
  • Revenues ($M)
  • Revenue Percent Change
  • Profits ($M)
  • Profits Percent Change
  • Assets ($M)
  • Employees
  • Market Value — as of March 29, 2018 ($M)

America’s largest pharmaceutical distributor slips one spot on the 500 this year, but the continued strength of its distribution business–serving as the middleman between manufacturers and pharmacies–lifted revenues 3% in 2017. The acquisition of Rexall Health powered some of that growth as did trends like the nation’s climbing drug prices and rising drug utilization rates. McKesson also moved ahead with its plan to divest its technology businesses in deals with Change Healthcare and Allscripts. The company, along with the country’s other large drug distributors, remains a target of litigation over its alleged role in the nation’s opioid epidemic.

Company Info

Figures are for fiscal year ended March 31, 2017.
John H. Hammergren
CEO Title
Chairman, President & Chief Executive Officer
Wholesalers: Health Care
HQ Location
San Francisco
Years on Fortune 500 List24

McKesson Rank History


Key Financials (Last Fiscal Year)

$ millions% change
Revenues ($M)$198,533.003.1%
Profits ($M)$5,070.00124.5%
Assets ($M)$60,969.00-
Total Stockholder Equity ($M)$11,095.00-
Market Value — as of March 29, 2018 ($M)$29,067.00-

Profit Ratios

Profit as % of Revenues2.6%
Profits as % of Assets8.3%
Profits as % of Stockholder Equity45.7%

Earnings Per Share (Last Fiscal Year)

Earnings Per Share ($)22.73
EPS % Change (from 2016)134.3%
EPS % Change (5 year annual rate)32.4%
EPS % Change (10 year annual rate)22.5%

Total Return

Total Return to Investors (2017)11.9%
Total Return to Investors (5 year, annualized)10.7%
Total Return to Investors (10 year, annualized)9.9%